81 related articles for article (PubMed ID: 20008849)
1. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
Banck MS; Grothey A
Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
3. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Van Cutsem E
Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers in the treatment of metastatic colorectal cancer.
Wilson PM; Labonte MJ; Lenz HJ
Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
7. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
8. Development of molecular biomarkers in individualized treatment of colorectal cancer.
De Mattos-Arruda L; Dienstmann R; Tabernero J
Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
[TBL] [Abstract][Full Text] [Related]
9. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
[TBL] [Abstract][Full Text] [Related]
11. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
Rougier P; Mitry E
Gastroenterol Clin Biol; 2009; 33(8-9):672-80. PubMed ID: 19717258
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer in review: the role of the EGFR pathway.
Saif MW
Expert Opin Investig Drugs; 2010 Mar; 19(3):357-69. PubMed ID: 20095919
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer.
Sobani ZA; Sawant A; Jafri M; Correa AK; Sahin IH
World J Clin Oncol; 2016 Oct; 7(5):340-351. PubMed ID: 27777877
[TBL] [Abstract][Full Text] [Related]
14. Integrating biomarkers into clinical decision making for colorectal cancer.
Wilson PM; Lenz HJ
Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S16-27. PubMed ID: 20630847
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer.
Valenzuela G; Burotto M; Marcelain K; González-Montero J
World J Gastrointest Oncol; 2022 Sep; 14(9):1654-1664. PubMed ID: 36187383
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer: From Genetic Landscape to Targeted Therapy.
El Bali M; Bakkach J; Bennani Mechita M
J Oncol; 2021; 2021():9918116. PubMed ID: 34326875
[TBL] [Abstract][Full Text] [Related]
17. Molecular Profiling of EGFR Status to Identify Skin Toxicity in Colorectal Cancer: A Clinicopathological Review.
Popa CM; Lungulescu C; Ianoși SL; Cherciu I; Schenker M; Săftoiu A
Curr Health Sci J; 2019; 45(2):127-133. PubMed ID: 31624638
[TBL] [Abstract][Full Text] [Related]
18. Markers of resistance to anti-EGFR therapy in colorectal cancer.
Shaib W; Mahajan R; El-Rayes B
J Gastrointest Oncol; 2013 Sep; 4(3):308-18. PubMed ID: 23997942
[TBL] [Abstract][Full Text] [Related]
19. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.
Lea A; Allingham-Hawkins D; Levine S
PLoS Curr; 2010 Oct; 2():RRN1187. PubMed ID: 20972475
[TBL] [Abstract][Full Text] [Related]
20. Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.
Loong HH; Ma BB; Chan AT
J Oncol; 2009; 2009():967920. PubMed ID: 19365583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
